{"id":"antidepressant-therapy","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Nausea"},{"rate":"10-20","effect":"Headache"},{"rate":"10-40","effect":"Sexual dysfunction"},{"rate":"10-25","effect":"Insomnia or somnolence"},{"rate":"5-15","effect":"Weight gain"},{"rate":"5-15","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL4298181","moleculeType":"Gene"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Antidepressants typically increase the availability of neurotransmitters such as serotonin, norepinephrine, or dopamine in synaptic spaces by inhibiting their reuptake or through other mechanisms. This enhanced neurotransmitter signaling helps restore mood regulation and alleviates depressive symptoms. The specific mechanism varies by drug class (SSRIs, SNRIs, tricyclics, MAOIs, etc.).","oneSentence":"Antidepressant therapy works by modulating neurotransmitter levels in the brain to alleviate symptoms of depression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:27:27.081Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder (select agents)"},{"name":"Obsessive-compulsive disorder (select agents)"},{"name":"Post-traumatic stress disorder (select agents)"}]},"trialDetails":[{"nctId":"NCT07494305","phase":"PHASE2","title":"Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.","status":"RECRUITING","sponsor":"LB Pharmaceuticals Inc.","startDate":"2026-01-23","conditions":"Bipolar I Disorder","enrollment":320},{"nctId":"NCT03947827","phase":"PHASE3","title":"Minocycline as Adjunctive Treatment for Treatment Resistant Depression","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2020-02-01","conditions":"Treatment Resistant Depression","enrollment":76},{"nctId":"NCT07361796","phase":"NA","title":"The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-12-15","conditions":"Herpes Zoster, Pain, Postherpetic Neuralgia","enrollment":832},{"nctId":"NCT07480486","phase":"NA","title":"Pharmacogenetic-Guided Antidepressant Treatment in Depression","status":"NOT_YET_RECRUITING","sponsor":"Mohammed V University in Rabat","startDate":"2026-04-01","conditions":"Depression - Major Depressive Disorder","enrollment":570},{"nctId":"NCT07226661","phase":"PHASE2","title":"Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder","status":"RECRUITING","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2026-01-19","conditions":"Major Depressive Disorder (MDD)","enrollment":230},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT06731621","phase":"PHASE1","title":"Psilocybin for Treatment-Resistant Depression in Autism","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2024-11-01","conditions":"Treatment Resistant Depression, Autism Spectrum Disorder","enrollment":20},{"nctId":"NCT06340958","phase":"PHASE2","title":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","status":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","startDate":"2024-03-18","conditions":"Adjunctive Treatment of Major Depressive Disorder (MDD)","enrollment":99},{"nctId":"NCT03844412","phase":"PHASE2","title":"Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-11-04","conditions":"Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome","enrollment":209},{"nctId":"NCT07396272","phase":"PHASE2","title":"A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression","status":"RECRUITING","sponsor":"Daniel Lindqvist","startDate":"2026-04-01","conditions":"Major Depressive Disorder (MDD)","enrollment":12},{"nctId":"NCT07345117","phase":"NA","title":"Cost-effectiveness and Implementation of a Transdiagnostic Internet-based Intervention for Emotional Disorders in Community Care.","status":"NOT_YET_RECRUITING","sponsor":"Universitat Jaume I","startDate":"2026-04-01","conditions":"Emotional Disorders, Depression Anxiety Disorder, Depression Disorders","enrollment":200},{"nctId":"NCT07480525","phase":"NA","title":"Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-20","conditions":"Depression - Major Depressive Disorder","enrollment":200},{"nctId":"NCT07015944","phase":"NA","title":"Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan","status":"RECRUITING","sponsor":"Pakistan Institute of Living and Learning","startDate":"2025-06-13","conditions":"Major Depressive Disorder (MDD), Breast Cancer Survivor","enrollment":26376},{"nctId":"NCT06423430","phase":"NA","title":"Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)","status":"RECRUITING","sponsor":"Abbott Medical Devices","startDate":"2024-09-11","conditions":"Treatment Resistant Depression","enrollment":100},{"nctId":"NCT06559306","phase":"PHASE3","title":"Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-07-25","conditions":"Depressive Disorder, Major","enrollment":752},{"nctId":"NCT06580860","phase":"","title":"Psychiatric Multi-omics and Neuroimaging Project","status":"RECRUITING","sponsor":"mingjun Zhong","startDate":"2016-01","conditions":"Mental Disorders, Healthy Control","enrollment":1899},{"nctId":"NCT05841030","phase":"","title":"A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-28","conditions":"Depressive Disorder, Major","enrollment":545},{"nctId":"NCT07284667","phase":"PHASE2","title":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","status":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2025-11-14","conditions":"Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant","enrollment":153},{"nctId":"NCT07452341","phase":"NA","title":"Effect of Virtual Reality on Depression in Adolescent Females","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-08-01","conditions":"Depression","enrollment":48},{"nctId":"NCT06402955","phase":"PHASE2","title":"Imaging Depression in Parkinson's Disease","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-09-01","conditions":"Parkinson's Disease, Major Depressive Disorder","enrollment":120},{"nctId":"NCT06604520","phase":"PHASE2","title":"Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-03-20","conditions":"Fronto-temporal Dementia, Fronto-temporal Lobar Dementia, Frontotemporal Degeneration","enrollment":50},{"nctId":"NCT06408246","phase":"PHASE2","title":"ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression","status":"RECRUITING","sponsor":"Stanford University","startDate":"2026-03-03","conditions":"Depression","enrollment":162},{"nctId":"NCT05710887","phase":"PHASE2","title":"N2O for Acute Suicidality and Depression in the ED","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2026-02-27","conditions":"Suicidal Ideation, Major Depressive Disorder, Treatment Resistant Depression","enrollment":""},{"nctId":"NCT06832605","phase":"NA","title":"Mindfulness-Based Cognitive Therapy (MBCT) for the Prevention of Depression Relapse or Recurrence Using Videoconference","status":"NOT_YET_RECRUITING","sponsor":"Fundació Sant Joan de Déu","startDate":"2026-04","conditions":"Major Depressive Disorder, Recurrent, in Remission","enrollment":315},{"nctId":"NCT07432815","phase":"PHASE4","title":"Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-02-01","conditions":"Depression, Anxiety, Psoriasis","enrollment":40},{"nctId":"NCT03973268","phase":"PHASE1","title":"Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression","status":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2020-01-21","conditions":"Depression, Major Depressive Disorder, Major Depression","enrollment":70},{"nctId":"NCT07430046","phase":"PHASE2","title":"Repurposing Mirtazapine in Rett Syndrome","status":"RECRUITING","sponsor":"University of Trieste","startDate":"2025-07-09","conditions":"RETT Syndrome With Proven MECP2 Mutation","enrollment":54},{"nctId":"NCT06922812","phase":"NA","title":"IWLS for Major Depressive Disorder: An Open-Label Study of Safety, Tolerability, and Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo","startDate":"2025-05-05","conditions":"Major Depressive Disorder (MDD)","enrollment":30},{"nctId":"NCT07266545","phase":"PHASE4","title":"RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-02-17","conditions":"Unipolar Depression, Bipolar Depression","enrollment":120},{"nctId":"NCT05593029","phase":"PHASE2","title":"A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-09","conditions":"Major Depressive Disorder","enrollment":929},{"nctId":"NCT07076342","phase":"PHASE4","title":"The Role of mGluR5 in CBT-I","status":"RECRUITING","sponsor":"Stony Brook University","startDate":"2025-08-01","conditions":"Major Depressive Disorder (MDD)","enrollment":42},{"nctId":"NCT06514742","phase":"PHASE3","title":"A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2024-06-26","conditions":"Depressive Disorder, Major, Anhedonia","enrollment":101},{"nctId":"NCT05550532","phase":"PHASE3","title":"A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-12-06","conditions":"Depressive Disorder, Major, Anhedonia","enrollment":444},{"nctId":"NCT07392879","phase":"NA","title":"Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-12-15","conditions":"Progressive Multiple Sclerosis, Depression","enrollment":40},{"nctId":"NCT07373470","phase":"NA","title":"An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.","status":"NOT_YET_RECRUITING","sponsor":"University of Pittsburgh","startDate":"2026-03","conditions":"Pharmacogenetics, Depression - Major Depressive Disorder, Pharmacogenomic Drug Interaction","enrollment":220},{"nctId":"NCT07047651","phase":"PHASE4","title":"Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","status":"RECRUITING","sponsor":"Dr. Stavroula Rakitzi","startDate":"2025-06-04","conditions":"Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder","enrollment":40},{"nctId":"NCT03674138","phase":"NA","title":"Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-09-12","conditions":"Depression, Anxiety, Generalized Anxiety Disorder","enrollment":99},{"nctId":"NCT06731101","phase":"NA","title":"Stellate Ganglion Block Versus Oral Medication in Treatment of Palmar Hyperhidrosis","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2025-01-15","conditions":"Palmar Hyperhidrosis","enrollment":46},{"nctId":"NCT07384273","phase":"NA","title":"Evaluating the Effectiveness of an Internet-based Therapy (iCARE) to Treat Symptoms of Postpartum Depression","status":"RECRUITING","sponsor":"University of Southern Denmark","startDate":"2026-02-01","conditions":"Postpartum Depression (PPD)","enrollment":352},{"nctId":"NCT06524830","phase":"PHASE2","title":"A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)","status":"RECRUITING","sponsor":"atai Therapeutics, Inc.","startDate":"2024-12-30","conditions":"Treatment Resistant Depression","enrollment":142},{"nctId":"NCT06805851","phase":"","title":"Impact of Depression on Thermoregulation","status":"RECRUITING","sponsor":"Penn State University","startDate":"2025-03-01","conditions":"Depression, Selective Serotonin Reuptake Inhibitor","enrollment":64},{"nctId":"NCT07384312","phase":"NA","title":"Study on the Antidepressant Effects and Mechanism of Action of Cang-ai Volatile Oil Based on Near-Infrared Functional Brain Imaging and the NT-Trk Signalling Pathway","status":"COMPLETED","sponsor":"Dongdong Qin","startDate":"2023-10-01","conditions":"Depression Disorder","enrollment":60},{"nctId":"NCT05814640","phase":"PHASE1, PHASE2","title":"Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-02-20","conditions":"Depression, Sequestra","enrollment":520},{"nctId":"NCT07228468","phase":"NA","title":"Home-Based Transcranial Direct Current Stimulation In Major Depressive Disorder (HOME)","status":"RECRUITING","sponsor":"King's College London","startDate":"2025-11-18","conditions":"Major Depressive Disorder (MDD)","enrollment":438},{"nctId":"NCT06846320","phase":"PHASE2","title":"Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-04-29","conditions":"Generalized Anxiety Disorder (GAD)","enrollment":315},{"nctId":"NCT05516095","phase":"NA","title":"The Antidepressant Effect of Intermittent Theta Burst Stimulation (iTBS)","status":"COMPLETED","sponsor":"University Hospital of North Norway","startDate":"2022-06-04","conditions":"Depression, Executive Dysfunction","enrollment":73},{"nctId":"NCT06404099","phase":"PHASE2","title":"RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Duke University","startDate":"2024-08-12","conditions":"Long COVID, Long COVID-19, Hypersomnia","enrollment":361},{"nctId":"NCT06937476","phase":"NA","title":"Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole","status":"RECRUITING","sponsor":"Central South University","startDate":"2025-05-08","conditions":"Major Depressive Disorder (MDD), Rumination","enrollment":108},{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT06404086","phase":"PHASE2","title":"RECOVER-SLEEP: Platform Protocol","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-07-31","conditions":"Long COVID, Long COVID-19, Hypersomnia","enrollment":830},{"nctId":"NCT04747314","phase":"PHASE2, PHASE3","title":"Treating Negative Affect in Low Back Pain Patients","status":"COMPLETED","sponsor":"Ajay Wasan, MD, Msc","startDate":"2021-03-31","conditions":"Chronic Low Back Pain, Negative Affectivity","enrollment":308},{"nctId":"NCT05913947","phase":"PHASE4","title":"Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)","status":"RECRUITING","sponsor":"Aalborg University Hospital","startDate":"2022-12-13","conditions":"Depression, Bipolar","enrollment":122},{"nctId":"NCT06633016","phase":"PHASE2","title":"Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)","status":"RECRUITING","sponsor":"Autobahn Therapeutics, Inc.","startDate":"2024-09-20","conditions":"Major Depressive Disorder","enrollment":230},{"nctId":"NCT07348952","phase":"NA","title":"Different Transcutaneous Electrical Nerve Stimulation Modes in Pudendal Neuralgia Post-prostatectomy","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-09-01","conditions":"Transcutaneous Electrical Nerve Stimulation, Pudendal Neuralgia, Post Prostatectomy","enrollment":60},{"nctId":"NCT05357040","phase":"PHASE2","title":"Antidepressant Effects of Nitrous Oxide","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2021-06-30","conditions":"Major Depressive Disorder, Treatment Resistant Depression","enrollment":172},{"nctId":"NCT07328373","phase":"","title":"Neurobiological and Genomic Predictors of Relapse in Depression","status":"RECRUITING","sponsor":"Mehmet Kemal Arikan","startDate":"2025-01-01","conditions":"Healthy, Major Depressive Disorder (MDD)","enrollment":204},{"nctId":"NCT06788249","phase":"EARLY_PHASE1","title":"Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-02-01","conditions":"Major Depressive Disorder (MDD)","enrollment":10},{"nctId":"NCT06976840","phase":"NA","title":"Rapid Antidepressant Dynamics in Acute Neuromodulation Treatments","status":"NOT_YET_RECRUITING","sponsor":"Marta Peciña, MD PhD","startDate":"2026-04","conditions":"Depression, Major Depressive Disorder","enrollment":200},{"nctId":"NCT06450704","phase":"NA","title":"Cerebral and Anti-inflammatory Response Through Exercise - Mechanisms In Depressive Disorders","status":"RECRUITING","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2025-04-21","conditions":"Major Depressive Disorder, Inflammatory Response","enrollment":124},{"nctId":"NCT06672419","phase":"NA","title":"Effectiveness of AI-Guided Exercise and Pain Neuroscience Education for Fibromyalgia (FIBROIA)","status":"NOT_YET_RECRUITING","sponsor":"Instituto Neurociencia Del Dolor","startDate":"2026-02-01","conditions":"Fibromyalgia, Fibromyalgia Syndrome","enrollment":50},{"nctId":"NCT06965569","phase":"PHASE1","title":"Multiple Ascending Dose Phase 1 Study of ALA-3000","status":"COMPLETED","sponsor":"Alar Pharmaceuticals Inc.","startDate":"2025-04-21","conditions":"Treatment Resistant Depression","enrollment":37},{"nctId":"NCT07115381","phase":"NA","title":"A Study on the Intervention Effect of Therapeutic Horticulture Based on the Healing System on Non-suicidal Self-injury in Adolescent Patients With Depression","status":"NOT_YET_RECRUITING","sponsor":"Lei Huang","startDate":"2026-02","conditions":"Depression","enrollment":66},{"nctId":"NCT06723249","phase":"NA","title":"Stingless Bee Honey Augmentation in Major Depressive Disorders","status":"COMPLETED","sponsor":"Hospital Universiti Sains Malaysia","startDate":"2024-12-15","conditions":"Major Depressive Disorder (MDD)","enrollment":45},{"nctId":"NCT00308893","phase":"PHASE4","title":"BDNF Gene Polymorphism and Antidepressants Treatment","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2006-07","conditions":"Depression","enrollment":188},{"nctId":"NCT07003763","phase":"NA","title":"Electroacupuncture on Treating Cancer-related Depression","status":"RECRUITING","sponsor":"Shanghai Municipal Hospital of Traditional Chinese Medicine","startDate":"2025-07-01","conditions":"Depression, Cancer","enrollment":86},{"nctId":"NCT00792168","phase":"PHASE4","title":"Physiologic Monitoring of Antidepressant Response","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"1996-11","conditions":"Major Depression","enrollment":38},{"nctId":"NCT06773949","phase":"NA","title":"Feasibility Trial of Exercise as a Priming Strategy for rTMS Treatment in Difficult-to-Treat Depression","status":"RECRUITING","sponsor":"The Royal Ottawa Mental Health Centre","startDate":"2025-12-15","conditions":"Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)","enrollment":20},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT07180342","phase":"NA","title":"An Empirical Study on the Mechanisms of Biopsychosocial Functional Improvement in Patients With Major Depressive Disorder Through Nature-Based Tourism Activities","status":"RECRUITING","sponsor":"Shandong Provincial Hospital","startDate":"2025-10-09","conditions":"Major Depressive Disorder","enrollment":86},{"nctId":"NCT04491045","phase":"NA","title":"Implementation Strategies for Task-Shifting Depression Care Depression Care in Vietnam","status":"COMPLETED","sponsor":"City University of New York, School of Public Health","startDate":"2021-12-01","conditions":"Depression","enrollment":1382},{"nctId":"NCT06511908","phase":"PHASE2","title":"Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression","status":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2024-11-06","conditions":"Suicide, Depressive Disorder, Treatment-Resistant, Ketamine","enrollment":50},{"nctId":"NCT06034821","phase":"PHASE4","title":"Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan","status":"ENROLLING_BY_INVITATION","sponsor":"Brigham and Women's Hospital","startDate":"2023-10-01","conditions":"Acute Suicidal Depression (ASD)","enrollment":1500},{"nctId":"NCT05966532","phase":"","title":"Emotional Cognition: Establishing Constructs and Neural-Behavioral Mechanisms in Older Adults With Depression","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-12-11","conditions":"Major Depressive Disorder (MDD), Healthy Adult Volunteer","enrollment":276},{"nctId":"NCT03640624","phase":"NA","title":"Multidisciplinary Treatment of Chronic Vulvar Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Norwegian University of Science and Technology","startDate":"2018-09-18","conditions":"Vulvodynia, Chronic Pain","enrollment":106},{"nctId":"NCT03553095","phase":"NA","title":"Comparing Inflammatory Markers in Patients With and Without Depression With Chronic Periodontitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2018-07-12","conditions":"Chronic Periodontitis, Depression","enrollment":92},{"nctId":"NCT06002100","phase":"","title":"Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements","status":"ENROLLING_BY_INVITATION","sponsor":"Kernel","startDate":"2023-08-14","conditions":"Depression, Major Depressive Disorder","enrollment":540},{"nctId":"NCT06907134","phase":"NA","title":"The Purpose of the Study is to Investigate if a Smartphone App Combined With Internet Based Cognitive Behavioural Therapy (ICBT) Leads to Improved Symtoms in Depressive Adults on Antidepressive Medicine, Compared to a Wait-list Control Condition","status":"ACTIVE_NOT_RECRUITING","sponsor":"Linkoeping University","startDate":"2024-11-02","conditions":"Depressive Symptoms","enrollment":150},{"nctId":"NCT03466346","phase":"NA","title":"SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-08-31","conditions":"Depression, Unipolar, Posttraumatic Stress Disorder, Trauma","enrollment":2162},{"nctId":"NCT06692361","phase":"NA","title":"Assessment of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Major Depressive Disorder","status":"RECRUITING","sponsor":"Gang Wang","startDate":"2025-01-01","conditions":"Major Depressive Disorder (MDD), Depression - Major Depressive Disorder","enrollment":214},{"nctId":"NCT05732298","phase":"NA","title":"Theta Burst Stimulation in Pharmacologically Untreated Patients as Sole Antidepressant Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Regensburg","startDate":"2023-02-27","conditions":"Depression","enrollment":72},{"nctId":"NCT07239011","phase":"PHASE1, PHASE2","title":"Dapagliflozin in Depression","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-01","conditions":"Depression","enrollment":60},{"nctId":"NCT06526078","phase":"NA","title":"Cognitive Training as an Adjunct to Ketamine in Real-world Clinics","status":"ENROLLING_BY_INVITATION","sponsor":"University of Pittsburgh","startDate":"2024-11-12","conditions":"Depression","enrollment":600},{"nctId":"NCT06384209","phase":"NA","title":"The Friendship Bench Plus Trial","status":"RECRUITING","sponsor":"University of Bern","startDate":"2025-06-26","conditions":"Major Depressive Disorder, Severe Depressive Episode Without Psychotic Symptoms","enrollment":296},{"nctId":"NCT06831942","phase":"NA","title":"Attempted Suicide Short Intervention Program for Older Adults (ASSIP-OA): An Evaluation of a Psychosocial Intervention for Suicidal Adults Aged 65+","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2025-10-01","conditions":"Suicidal Ideation, Suicide Attempt, Suicide","enrollment":132},{"nctId":"NCT05455684","phase":"PHASE3","title":"A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-06-22","conditions":"Depressive Disorder, Major, Anhedonia","enrollment":513},{"nctId":"NCT04855747","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Levomecor Inc.","startDate":"2021-03-30","conditions":"Major Depressive Disorder, Depression","enrollment":236},{"nctId":"NCT06011577","phase":"PHASE3","title":"Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD","status":"TERMINATED","sponsor":"Levomecor Inc.","startDate":"2023-08-17","conditions":"Major Depressive Disorder, Depression","enrollment":27},{"nctId":"NCT05944926","phase":"PHASE3","title":"Improving Outcomes in Depression in Primary Care in a Low Resource Setting","status":"RECRUITING","sponsor":"Harvard Medical School (HMS and HSDM)","startDate":"2024-03-18","conditions":"Depression, Depressive Disorder","enrollment":1500},{"nctId":"NCT05575128","phase":"NA","title":"Behavioral Activation and Medication Optimization In Older Adults Undergoing Cardiac Procedures","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2022-11-05","conditions":"Cardiac Surgery, Older Adults, Depression","enrollment":102},{"nctId":"NCT05060549","phase":"PHASE4","title":"Dopamine D3 Receptor Occupancy in Bipolar Depression","status":"NOT_YET_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2026-01-06","conditions":"Bipolar Depression","enrollment":8},{"nctId":"NCT04103892","phase":"PHASE2","title":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","status":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","startDate":"2019-09-05","conditions":"Adjunctive Treatment of Major Depressive Disorder","enrollment":146},{"nctId":"NCT04560660","phase":"PHASE2","title":"Ketamine-enhanced Prolonged Exposure Therapy in PTSD","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2021-03-09","conditions":"PTSD","enrollment":75},{"nctId":"NCT07211984","phase":"NA","title":"Evaluation of Dalia Solution For Depressed Patient","status":"NOT_YET_RECRUITING","sponsor":"Dalia Care","startDate":"2025-10-10","conditions":"Depression Chronic, Depressed, Depressed Mood","enrollment":644},{"nctId":"NCT05989451","phase":"NA","title":"Adaptation of Individual Dialectical Behavior Therapy Intervention for Transdiagnostic Treatment of Emotional Disorders","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2023-09-01","conditions":"Anxiety Disorder, Depressive Disorder","enrollment":250},{"nctId":"NCT04111627","phase":"PHASE2","title":"Exercise Plus Duloxetine for Knee Osteoarthritis","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2021-10-07","conditions":"Knee Osteoarthritis, Depression","enrollment":43},{"nctId":"NCT05415397","phase":"PHASE3","title":"Treating Immuno-metabolic Depression With Anti-inflammatory Drugs","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2022-09-28","conditions":"Depressive Disorder, Major, Inflammation","enrollment":140},{"nctId":"NCT02751632","phase":"PHASE3","title":"The Staged Treatment in Early Psychosis Study","status":"COMPLETED","sponsor":"Orygen","startDate":"2016-04","conditions":"Psychotic Disorders, Personality Disorders, Clinical High Risk","enrollment":342},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT05973851","phase":"PHASE3","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2024-08-31","conditions":"Major Depressive Disorder, Treatment Resistant Depression","enrollment":418},{"nctId":"NCT07192367","phase":"PHASE4","title":"Comparison of the Effectiveness Level of Virtual Reality Exposure Therapy With Sertraline Treatment in Social Anxiety Disorder","status":"RECRUITING","sponsor":"Emine Kanmaz","startDate":"2024-11-15","conditions":"Social Anxiety Disorder","enrollment":56}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABNORMAL BEHAVIOUR"},{"count":1,"reaction":"DEATH"},{"count":1,"reaction":"DEPRESSION"},{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"DRUG INTERACTION"},{"count":1,"reaction":"INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION"},{"count":1,"reaction":"NERVOUSNESS"},{"count":1,"reaction":"PARANOIA"},{"count":1,"reaction":"SEROTONIN SYNDROME"},{"count":1,"reaction":"THERAPEUTIC PRODUCT INEFFECTIVE"}],"_approvalHistory":[],"publicationCount":2430,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fluoxetine","Amitriptyline"],"phase":"marketed","status":"active","brandName":"Antidepressant Therapy","genericName":"Antidepressant Therapy","companyName":"RAND","companyId":"rand","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antidepressant therapy works by modulating neurotransmitter levels in the brain to alleviate symptoms of depression. Used for Major depressive disorder, Generalized anxiety disorder (select agents), Obsessive-compulsive disorder (select agents).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}